Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Pacer Advisors Inc.

Pacer Advisors Inc. grew its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 29.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,752,882 shares of the specialty pharmaceutical company’s stock after buying an additional 403,028 shares during the period. Pacer Advisors Inc. owned about 3.17% of Supernus Pharmaceuticals worth $54,655,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its position in Supernus Pharmaceuticals by 205.2% during the 1st quarter. Russell Investments Group Ltd. now owns 97,988 shares of the specialty pharmaceutical company’s stock valued at $3,342,000 after purchasing an additional 65,880 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Supernus Pharmaceuticals by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock worth $45,077,000 after acquiring an additional 351,900 shares during the period. Bank of Montreal Can lifted its position in Supernus Pharmaceuticals by 1,508.0% in the 2nd quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock valued at $3,287,000 after purchasing an additional 109,088 shares during the last quarter. Candriam S.C.A. acquired a new position in Supernus Pharmaceuticals during the 2nd quarter valued at about $3,795,000. Finally, Stephens Investment Management Group LLC grew its position in Supernus Pharmaceuticals by 1.8% in the 3rd quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after purchasing an additional 33,710 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on SUPN. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th.

Insider Activity at Supernus Pharmaceuticals

In related news, CEO Jack A. Khattar sold 125,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the completion of the sale, the chief executive officer now owns 926,172 shares of the company’s stock, valued at $33,971,988.96. This trade represents a 11.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Frank Mottola sold 15,000 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the sale, the senior vice president now owns 8,200 shares of the company’s stock, valued at approximately $303,236. The trade was a 64.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 154,213 shares of company stock valued at $5,660,180 over the last quarter. 9.30% of the stock is owned by company insiders.

Supernus Pharmaceuticals Trading Down 0.8 %

Shares of Supernus Pharmaceuticals stock opened at $35.82 on Friday. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $39.37. The company has a market cap of $1.98 billion, a P/E ratio of 33.48 and a beta of 0.86. The stock has a 50-day moving average price of $33.62 and a 200 day moving average price of $31.06.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. During the same period in the prior year, the firm posted ($0.29) EPS. The business’s revenue was up 14.2% compared to the same quarter last year. On average, equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.